In a 96.6 kg patient with type 1 diabetes receiving D5W at 125 mL/hr and a continuous insulin infusion of 3 U/h, what should be the basal insulin (insulin glargine/Lantus) dose, insulin sensitivity factor, and insulin‑to‑carbohydrate ratio?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Calculating Insulin Parameters for Transition from IV to Subcutaneous Insulin

Based on the current insulin infusion rate of 3 units/hour (72 units/day), the recommended Lantus dose is approximately 36 units once daily, with an insulin sensitivity factor (ISF) of 27 mg/dL per unit and an insulin-to-carbohydrate ratio (ICR) of approximately 1:9.

Basal Insulin (Lantus) Dose Calculation

The patient is currently receiving 3 units/hour × 24 hours = 72 units total daily dose (TDD) of insulin intravenously. When transitioning from IV insulin to subcutaneous basal-bolus therapy in type 1 diabetes:

  • Basal insulin should comprise approximately 50% of the TDD 1, 2
  • Therefore: 72 units × 0.5 = 36 units of Lantus once daily

The FDA label for Lantus confirms that in type 1 diabetes, approximately one-third of total daily insulin requirements should be given as basal insulin, with the remainder as prandial insulin 3. However, the most recent ADA guidelines emphasize the 50/50 split between basal and prandial insulin as the standard approach 1, 2.

Important Considerations:

  • The patient is receiving D5W at 125 mL/hr, providing approximately 150 grams of carbohydrate per day (125 mL/hr × 24 hr × 5 g/100 mL)
  • This continuous glucose infusion is currently being covered by the insulin drip
  • Once transitioned to subcutaneous insulin, the D5W should be discontinued to avoid hyperglycemia, or prandial insulin must be adjusted to cover this carbohydrate load

Insulin Sensitivity Factor (ISF)

Using the validated formula from research on optimal insulin dosing 4:

ISF = 1960 ÷ TDD

  • ISF = 1960 ÷ 72 = 27 mg/dL per unit

This means 1 unit of rapid-acting insulin will lower blood glucose by approximately 27 mg/dL.

Alternative calculation methods exist (1800 rule or 1500 rule), but the 1960 formula has been validated in patients with optimal glucose control 4.

Insulin-to-Carbohydrate Ratio (ICR)

Using the validated weight-based formula 4:

ICR = (2.6 × Weight in pounds) ÷ TDD

  • Weight: 96.6 kg = 213 pounds
  • ICR = (2.6 × 213) ÷ 72 = 554 ÷ 72 = 7.7, rounded to 1:8 or 1:9

This means 1 unit of rapid-acting insulin will cover approximately 8-9 grams of carbohydrate. Start conservatively with 1:9 and titrate based on postprandial glucose readings.

Transition Protocol

When converting from IV insulin to subcutaneous therapy 5:

  1. Administer the first dose of Lantus 2-4 hours before discontinuing the insulin drip to ensure adequate basal coverage
  2. Continue IV insulin until Lantus has begun to take effect (approximately 2-4 hours after injection)
  3. Discontinue D5W infusion when transitioning to meal-based carbohydrate intake
  4. Provide rapid-acting insulin (lispro, aspart, or glulisine) for meals and corrections:
    • Prandial insulin: approximately 36 units/day divided among meals based on carbohydrate content
    • Correction doses using the ISF of 1:27

Critical Pitfalls to Avoid:

  • Never stop basal insulin in type 1 diabetes, even if the patient is NPO 6, 7. This patient must receive Lantus continuously to prevent diabetic ketoacidosis
  • Do not abruptly discontinue IV insulin without overlapping subcutaneous basal coverage—this creates a dangerous gap in insulin delivery 5
  • The 0.5 units/kg/day rule (which would suggest 48 units TDD for this 96.6 kg patient) is a starting point for newly diagnosed patients 1, 2, but this patient's current insulin requirement of 72 units/day reflects their actual needs under stress/hospitalization
  • Monitor closely for hypoglycemia when discontinuing D5W, as the patient will no longer have continuous carbohydrate intake

Dose Adjustments:

The Endocrine Society guidelines recommend using the "insulin-sensitive" correction scale initially for patients transitioning from IV insulin 5, then titrating based on response. If the patient was receiving steroids or has other insulin resistance factors, consider starting with the higher end of dosing recommendations.

Verify these calculations match the patient's home insulin regimen if previously established, as hospital insulin requirements may be 20-30% higher than outpatient needs due to stress, illness, and reduced activity 5.

References

Related Questions

In a 61‑year‑old male weighing 53 kg with normal renal function, what should his insulin sensitivity factor, insulin‑to‑carbohydrate ratio, and Lantus (insulin glargine) basal dose be?
Should I decrease my insulin glargine (Lantus) dose, currently 22 units, given a blood glucose of 219 mg/dL at 2 am and 152 mg/dL at 7 am?
My blood glucose remains in the 300–400 mg/dL range despite taking 8 units of insulin glargine (Lantus); how many additional units of insulin glargine should I increase to?
For a 19‑year‑old patient with type 1 diabetes weighing 86.2 kg who is currently taking insulin glargine (Lantus) 12 U at 08:00 and 35 U at 20:00 and uses insulin‑to‑carbohydrate ratios of 1 U per 5 g carbs for breakfast and lunch and 1 U per 6 g carbs for dinner, what should the basal Lantus dose and insulin‑to‑carbohydrate ratio be adjusted to?
In a 47-year-old male with uncontrolled diabetes (glucose 369 mg/dL) who has been off medication for over a year, can I initiate basal insulin with insulin glargine (Lantus) now?
Is Caplyta (lumateperone) less likely to cause weight gain compared to other atypical antipsychotics?
Does chronic alcoholism cause anemia and elevated mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH)?
Should a patient with internal hemorrhoids, hemoglobin 13 g/dL and low mean corpuscular hemoglobin (MCH) and mean corpuscular hemoglobin concentration (MCHC) be started on iron supplementation?
How should I manage a patient with serum vitamin B12 >2000 pg/mL who is receiving high‑dose B12 supplementation and is currently on metformin?
What is the recommended tapering schedule for a patient who has been taking gabapentin 100 mg twice daily long term?
What anti‑emetic medications are appropriate for a patient with benign paroxysmal positional vertigo (BPPV)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.